미국의 컴파운딩 약국 시장 규모, 점유율, 동향 분석 리포트 : 유형별, 치료 영역별, 연령 코호트별, 컴파운딩 유형별, 무균성별, 부문 예측(2024-2030년)

U.S. Compounding Pharmacies Market Growth & Trends:

The U.S. compounding pharmacies market size is anticipated to reach USD 7.18 billion by 2030 and is anticipated to grow at a CAGR of 4.89% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is poised for substantial growth, driven by rising awareness and adoption of compounded medications. The growing demand stems from increasing prescription volumes, frequent drug shortages, and manufacturer discontinuations of key medications. These shortages, impaired by supply chain disruptions and manufacturing delays issues that were intensified by the COVID-19 pandemic have increased the critical role of compounding pharmacies.

According to the FDA, drug shortages increased due to manufacturing restrictions, raw material shortages, and logistic delays during the pandemic. As a result, compounding pharmacies gained more opportunities to fill these gaps in drug availability. The FDA even issued temporary guidance allowing federally and state-licensed pharmacies to compound certain medications for hospitalized patients during public health emergencies. This combination of rising demand and regulatory support is expected to drive market expansion.

U.S. Compounding Pharmacies Market Report Highlights:

• Based on type, the 503A segment held the largest revenue share in 2023. This is attributed to the rising demand for personalized medications tailored to individual patient needs.
• Based on therapeutic area, the pain management segment dominated the market with the largest market share in 2023 due to its specialized approaches in alleviating the side effects of standard pain management medications.
• Based on age cohort, the adult segment dominated the market with the largest revenue share in 2023 due to factors such as allergies, specific dosage requirements, and preferences for other forms of medication.
• Based on compounding type, the pharmaceutical ingredient alteration (PIA) segment dominated the U.S. compounding pharmacies market in 2023 due to the high demand for customized drugs from patients with special needs.
• Based on sterility, the sterile segment dominated the market with the largest revenue share in 2023 due to the significant demand for intravenous sterile planning required by geriatric and pediatric patients.
• For instance, in February 2023, Harrow Health, Inc., a prominent U.S. eyecare pharmaceutical company, launched its patent-pending, next-generation compounded Atropine formulations, now accessible through its compounding and mail-order pharmacy subsidiary, ImprimisRx.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Market Definitions
  • 1.2.1. Type
  • 1.2.2. Therapeutic Area
  • 1.2.3. Age Cohort
  • 1.2.4. Compounding Type
  • 1.2.5. Sterility
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources & Third-Party Perspectives
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Increasing demand for personalized medications
    • 3.2.1.2. Growing importance of pharmaceutical compounding in promoting medication adherence
    • 3.2.1.3. Increasing supportive government policies
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Quality and safety concerns
    • 3.2.2.2. Chances of human errors or medication errors
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenges Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis

Chapter 4. Type Business Analysis

• 4.1. Type Segment Dashboard
• 4.2. U.S. Compounding Pharmacies Market: Type Movement Analysis
• 4.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Type, 2018 - 2030 (USD Million)
• 4.4. 503A
  • 4.4.1. 503A Market, 2018 - 2030 (USD Million)
• 4.5. 503B
  • 4.5.1. 503B Market, 2018 - 2030 (USD Million)

Chapter 5. Therapeutic Area Business Analysis

• 5.1. Therapeutic Area Segment Dashboard
• 5.2. U.S. Compounding Pharmacies Market: Therapeutic Area Movement Analysis
• 5.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Therapeutic Area, 2018 - 2030 (USD Million)
• 5.4. Pain Management
  • 5.4.1. Pain Management Market, 2018 - 2030 (USD Million)
• 5.5. Hormone Replacement Therapy
  • 5.5.1. Hormone Replacement Therapy Market, 2018 - 2030 (USD Million)
• 5.6. Specialty Drugs
  • 5.6.1. Specialty Drugs Market, 2018 - 2030 (USD Million)
• 5.7. Dermatology
  • 5.7.1. Dermatology Market, 2018 - 2030 (USD Million)
• 5.8. Nutritional Supplements
  • 5.8.1. Nutritional Supplements Market, 2018 - 2030 (USD Million)
• 5.9. Others
  • 5.9.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. Age Cohort Business Analysis

• 6.1. Age Cohort Segment Dashboard
• 6.2. U.S. Compounding Pharmacies Market: Age Cohort Movement Analysis
• 6.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Age Cohort, 2018 - 2030 (USD Million)
• 6.4. Pediatric
  • 6.4.1. Pediatric Market, 2018 - 2030 (USD Million)
• 6.5. Adult
  • 6.5.1. Adult Market, 2018 - 2030 (USD Million)
• 6.6. Geriatric
  • 6.6.1. Geriatric Market, 2018 - 2030 (USD Million)

Chapter 7. Compounding Type Business Analysis

• 7.1. Compounding Type Segment Dashboard
• 7.2. U.S. Compounding Pharmacies Market: Compounding Type Movement Analysis
• 7.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Compounding Type, 2018 - 2030 (USD Million)
• 7.4. Pharmaceutical Ingredient Alteration (PIA)
  • 7.4.1. Pharmaceutical Ingredient Alteration (PIA) Market, 2018 - 2030 (USD Million)
• 7.5. Currently Unavailable Pharmaceutical Manufacturing (CUPM)
  • 7.5.1. Currently Unavailable Pharmaceutical Manufacturing (CUPM) Market, 2018 - 2030 (USD Million)
• 7.6. Pharmaceutical Dosage Alteration (PDA)
  • 7.6.1. Pharmaceutical Dosage Alteration (PDA) Market, 2018 - 2030 (USD Million)

Chapter 8. Sterility Business Analysis

• 8.1. Sterility Segment Dashboard
• 8.2. U.S. Compounding Pharmacies Market: Sterility Movement Analysis
• 8.3. U.S. Compounding Pharmacies Market Size & Trend Analysis, by Sterility, 2018 - 2030 (USD Million)
• 8.4. Sterile
  • 8.4.1. Sterile Market, 2018 - 2030 (USD Million)
• 8.5. Non Sterile
  • 8.5.1. Non Sterile Market, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Company Categorization
• 9.2. Company Market Position Analysis
• 9.3. Strategy Mapping
• 9.4. Company Profiles/Listing
  • 9.4.1. Avella Specialty Pharmacy
    • 9.4.1.1. Overview
    • 9.4.1.2. Financial Performance
    • 9.4.1.3. Service Benchmarking
    • 9.4.1.4. Strategic Initiatives
  • 9.4.2. Central Admixture Pharmacy Services, Inc.
    • 9.4.2.1. Overview
    • 9.4.2.2. Financial Performance
    • 9.4.2.3. Service Benchmarking
    • 9.4.2.4. Strategic Initiatives
  • 9.4.3. Clinigen Limited
    • 9.4.3.1. Overview
    • 9.4.3.2. Financial Performance
    • 9.4.3.3. Service Benchmarking
    • 9.4.3.4. Strategic Initiatives
  • 9.4.4. Fagron
    • 9.4.4.1. Overview
    • 9.4.4.2. Financial Performance
    • 9.4.4.3. Service Benchmarking
    • 9.4.4.4. Strategic Initiatives
  • 9.4.5. Fresenius Kabi USA
    • 9.4.5.1. Overview
    • 9.4.5.2. Financial Performance
    • 9.4.5.3. Service Benchmarking
    • 9.4.5.4. Strategic Initiatives
  • 9.4.6. ImprimisRx (Harrow Health, Inc.)
    • 9.4.6.1. Overview
    • 9.4.6.2. Financial Performance
    • 9.4.6.3. Service Benchmarking
    • 9.4.6.4. Strategic Initiatives
  • 9.4.7. PenCol Pharmacy
    • 9.4.7.1. Overview
    • 9.4.7.2. Financial Performance
    • 9.4.7.3. Service Benchmarking
    • 9.4.7.4. Strategic Initiatives
  • 9.4.8. Sixth Avenue Medical Pharmacy
    • 9.4.8.1. Overview
    • 9.4.8.2. Financial Performance
    • 9.4.8.3. Service Benchmarking
    • 9.4.8.4. Strategic Initiatives
  • 9.4.9. Triangle Compounding
    • 9.4.9.1. Overview
    • 9.4.9.2. Financial Performance
    • 9.4.9.3. Service Benchmarking
    • 9.4.9.4. Strategic Initiatives
  • 9.4.10. Vertisis Custom Pharmacy
    • 9.4.10.1. Overview
    • 9.4.10.2. Financial Performance
    • 9.4.10.3. Service Benchmarking
    • 9.4.10.4. Strategic Initiatives